JAAD Mendeley Supplemental: Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study
Published: 22 February 2021| Version 1 | DOI: 10.17632/7psyyvctb6.1
Contributor:
Ai-Tram BuiDescription
JAAD Research Letter Supplemental Figure: Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study
Files
Categories
Dermatology